Gilead Sciences (NASDAQ:GILD – Free Report) had its target price lifted by Citigroup from $125.00 to $135.00 in a research report report published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. GILD has been the subject of a number of other research reports. UBS Group [...]
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00
